19 reports

  • ONCOLOGICAL PRURITUS

Being a dermatological condition, the topical formulation can give good local relief from itching sensations.

  • Dermatological Condition
  • Allergan plc
  • GlaxoSmithKline plc
  • Pfizer Inc.
  • Sanofi S.A.
  • 2.6 Epidemiology

Clinics in Dermatology; ##(##): ##-## Tran T-A (2017).

  • Dermatological Condition
  • World
  • AbbVie Inc.
  • Amryt Pharma plc
  • Celgene Corporation
  • 2.6.3 Psoriasis

Approximately one-third of the US population suffers from at least one active skin condition (Johnson, 2004).

  • Dermatological Condition
  • World
  • AbbVie Inc.
  • Allergan plc
  • Amgen Inc.
  • 1.1.1. FAST FACTS - GLOBAL DERMATOLOGICAL DRUGS MARKET
  • 2.1 CURRENT TRENDS, CHALLENGES AND DEVELOPMENTS

GMR DATA - FOR WHICH CONDITION IS THE DERMATOLOGICAL TREATMENT MARKET SHRINKING?

  • Dermatological Condition
  • World
  • Forecast
  • Allergan plc
  • Galderma S.A.
  • 4.1 ETIOLOGY AND PATHOPHYSIOLOGY

Dermatology; ##(##): ##-##.

  • Dermatological Condition
  • Foamix Ltd.
  • Galderma S.A.
  • Novan, Inc.
  • Valeant Pharmaceuticals International, Inc.
  • Clinical and Commercial Landscape
  • 4.4.3 Psoriasis

Approximately one third of the US population suffers from at least one active dermatological condition (Johnson, 2004).

  • Dermatological Condition
  • World
  • Market Size
  • Allergan plc
  • Apricus Biosciences, Inc.
  • LICENSING AGREEMENTS
  • LICENSING AGREEMENTS

Alopecia areata is an autoimmune dermatologic condition, typically characterized by patchy, non-scarring hair loss on the scalp and body.

  • Dermatological Condition
  • Therapy
  • United States
  • Company
  • Aclaris Therapeutics, Inc.

PHASE II TRIALS: Controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in patients with the disease or condition under study and to determine the common short-term side effects and risks.

  • Dermatological Condition
  • Pathology
  • Therapy
  • World
  • Product Initiative
  • Dec 07, 2015: Aclaris Therapeutics Initiates Phase 2 Clinical Trial of A-101 for Treatment of Common Warts

Warts - Pipeline Review, H1 2018 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Warts - Pipeline Review, H1 2018, provides an overview of the Warts (Infectious Disease) pipeline landscape. Warts are skin growth that is caused by virus called human...

  • Dermatological Condition
  • Pathology
  • Therapy
  • United States
  • Product Initiative
  • Latest Clinical Trials News on Epidermolysis Bullosa

EBS is the most common form of epidermolysis bullosa, a rare dermatologic condition where patients (many of them children) have a genetic defect that compromises the structural integrity of their skin, making it particularly fragile and prone to blistering over their entire bodies.

  • Dermatological Condition
  • Dermatology
  • World
  • Product Initiative
  • Amryt Pharma plc

Dermatological conditions are one of the most common types of disorders worldwide, and approximately one-third of the US population suffers from at least one active skin condition.

  • Dermatological Condition
  • World
  • Market Size
  • Amgen Inc.
  • Biologics, Inc.
  • Clinical and Commercial Landscape

Dermatology; ## (##).

  • Dermatological Condition
  • Pathology
  • Therapy
  • World
  • Deals & Alliance
  • AMG-0101 - DRUG PROFILE

There was no statistically significant difference between the NF-kappaB Decoy Oligonucleotide treated group and the placebo group in the primary end point of the improvement in the dermatological condition scores at week ##.

  • Dermatological Condition
  • Pharmaceutical
  • United States
  • Company
  • Product Initiative
  • JAN 15, 2018: CASTLE CREEK PHARMACEUTICALS ANNOUNCES DATA VALIDATING FIRST INVESTIGATOR'S GLOBAL ASSESSMENT SCALE FOR EPIDERMOLYSIS BULLOSA SIMPLEX CLINICAL RESEARCH

EBS is the most common form of epidermolysis bullosa, a rare dermatologic condition where patients, many of them children, have a genetic defect that compromises the structural integrity of their skin, making it particularly fragile and prone to blistering throughout their bodies.

  • Dermatological Condition
  • Hospital
  • Therapy
  • United States
  • Product Initiative
  • Latest Clinical Trials News on Atopic Dermatitis

" We now have an opportunity to further evaluate the unique range of pharmacological attributes of EISO in treating this important dermatological condition. "

  • Clinical Trial
  • Dermatological Condition
  • Pharmaceutical
  • World
  • Product Initiative
  • JAN 15, 2018: CASTLE CREEK PHARMACEUTICALS ANNOUNCES DATA VALIDATING FIRST INVESTIGATOR'S GLOBAL ASSESSMENT SCALE FOR EPIDERMOLYSIS BULLOSA SIMPLEX CLINICAL RESEARCH

EBS is the most common form of epidermolysis bullosa, a rare dermatologic condition where patients, many of them children, have a genetic defect that compromises the structural integrity of their skin, making it particularly fragile and prone to blistering throughout their bodies.

  • Dermatological Condition
  • Pharmaceutical
  • Therapy
  • United States
  • Product Initiative
  • AMG-0101 - DRUG PROFILE

There was no statistically significant difference between the NF-kappaB Decoy Oligonucleotide treated group and the placebo group in the primary end point of the improvement in the dermatological condition scores at week ##.

  • Dermatological Condition
  • Japan
  • World
  • Company Operations
  • Shionogi & Co., Ltd.
  • Product Development Milestones

Approximately one-third of the US population suffers from at least one active skin condition.

  • Acne Treatment
  • Dermatological Condition
  • United States
  • Company
  • Product Initiative

The drug candidate by blocking the activity of TGF-beta receptor type-## treats the condition.

  • Dermatological Condition
  • United States
  • Company
  • Product Initiative
  • Pfizer Inc.